Phase 1 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are male and aged 18 or older at the time of signing the consent form
- People who have been diagnosed with prostate cancer (adenocarcinoma type), confirmed through laboratory testing of tissue or cell samples
- For the dose escalation part of the trial: People whose prostate cancer has spread and is no longer responding to hormone therapy, and who have previously been treated with at least one newer hormone-blocking drug and at least one chemotherapy regimen containing a taxane drug — or who have declined taxane chemotherapy or been assessed as medically unsuitable to receive it
- For the dose expansion part of the trial: People who have received no more than two hormone-blocking therapies and no more than one prior taxane chemotherapy regimen at an earlier stage of their disease — or who have declined taxane chemotherapy or been assessed as medically unsuitable to receive it
- People whose liver, kidneys, and other organs are functioning at an adequate level (confirm with trial site)
Who may not be able to join:
- People who have previously received a solid organ transplant (such as a kidney, liver, or heart transplant)
- People who have previously received a type of immune cell treatment called CAR-T cell therapy, or certain other immune-based cancer therapies (approved or experimental), or a type of treatment called radioligand therapy
- People with serious heart or blood vessel disease
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +1 858-206-8471
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Dose Limiting Toxicities (DLTs); Incidence of adverse events (AE) and Serious Adverse Events (SAE)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.